Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Rupp

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Vaccine|March 22, 2018
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of ageSusan J Ermlich, Charles P Andrews, Steven Folkerth, et al.
Vaccine|January 11, 2025
Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59®Sharon E Frey, Rebecca Brady, Lisa Jackson, et al.
JAMA|October 8, 2014
Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trialMark J Mulligan, David I Bernstein, Patricia Winokur, et al.
Vaccine|January 24, 2021
Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and olderPatricia Winokur, Hana M El Sahly, Mark J Mulligan, et al.
The Journal of Infectious Diseases|September 20, 2019
Phase 1 Clinical Trial of a Conditionally Replication-Defective Human Cytomegalovirus (CMV) Vaccine in CMV-Seronegative SubjectsStuart P Adler, Nicole Lewis, Anthony Conlon, et al.
Vaccine|December 15, 2015
Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trialDavid I Bernstein, Flor M Munoz, S Todd Callahan, et al.
Vaccine|January 9, 2023
A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)Robert Lupinacci, Richard Rupp, Orasri Wittawatmongkol, et al.
Pediatrics|June 13, 2023
Safety and Tolerability of V114 Pneumococcal Vaccine in Infants: A Phase 3 StudyNatalie Banniettis, Michael Horn, Manish Sadarangani, et al.
Pediatrics|January 2, 2021
Three-Year Follow-up of 2-Dose Versus 3-Dose HPV VaccineJacob Bornstein, Surita Roux, Lone Kjeld Petersen, et al.
The Journal of Infectious Diseases|May 10, 2022
Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) TrialHana M El Sahly, Lindsey R Baden, Brandon Essink, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Vaccine|March 22, 2018
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of ageSusan J Ermlich, Charles P Andrews, Steven Folkerth, et al.
Vaccine|January 11, 2025
Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59®Sharon E Frey, Rebecca Brady, Lisa Jackson, et al.
JAMA|October 8, 2014
Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trialMark J Mulligan, David I Bernstein, Patricia Winokur, et al.
Vaccine|January 24, 2021
Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and olderPatricia Winokur, Hana M El Sahly, Mark J Mulligan, et al.
The Journal of Infectious Diseases|September 20, 2019
Phase 1 Clinical Trial of a Conditionally Replication-Defective Human Cytomegalovirus (CMV) Vaccine in CMV-Seronegative SubjectsStuart P Adler, Nicole Lewis, Anthony Conlon, et al.
Vaccine|December 15, 2015
Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trialDavid I Bernstein, Flor M Munoz, S Todd Callahan, et al.
Vaccine|January 9, 2023
A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)Robert Lupinacci, Richard Rupp, Orasri Wittawatmongkol, et al.
Pediatrics|June 13, 2023
Safety and Tolerability of V114 Pneumococcal Vaccine in Infants: A Phase 3 StudyNatalie Banniettis, Michael Horn, Manish Sadarangani, et al.
Pediatrics|January 2, 2021
Three-Year Follow-up of 2-Dose Versus 3-Dose HPV VaccineJacob Bornstein, Surita Roux, Lone Kjeld Petersen, et al.
The Journal of Infectious Diseases|May 10, 2022
Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) TrialHana M El Sahly, Lindsey R Baden, Brandon Essink, et al.
Pageof 5